Filippo Cademartiri: Treating Atherosclerosis Rather Than Its Probability
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared a post on X about a recent article by Eugenia Gianos et al, published in Journal of Clinical Lipidology, adding:
“We’ve Spent Decades Predicting Risk. Maybe It’s Time to Start Seeing Disease.
For years, preventive cardiology has debated two competing philosophies:
Treat based on risk factors.
Or…
Treat based on imaging.
This editorial argues that the new 2026 ACC/AHA Dyslipidemia Guideline may finally bring the two together. Imaging guided treatment of subclinical atherosclerosis—We’ve come a long way!.pdf
The proposed strategy is simple:
Estimate risk with PREVENT-ASCVD.
Refine uncertainty using risk enhancers.
Then, when needed, look directly for subclinical atherosclerosis with coronary imaging. Imaging guided treatment of subclinical atherosclerosis—We’ve come a long way!.pdf
The Critical Point
The most important message isn’t that CAC has become more prominent.
It’s why.
CAC is no longer viewed simply as another risk marker.
It is a marker of actual disease.
The guideline goes even further, recommending treatment intensity according to plaque burden, incorporating incidental CAC from routine chest CT, and introducing a selective role for CCTA in patients likely to harbor substantial non-calcified plaque.
The figure in the editorial illustrates this shift beautifully: LDL-C targets are no longer driven solely by estimated risk, but increasingly by the amount of coronary atherosclerosis already present. Imaging guided treatment of subclinical atherosclerosis—We’ve come a long way!.pdf
My Take
This is exactly the evolution many of us have been waiting for.
For decades we’ve treated the probability of disease.
We’re now beginning to treat the disease itself.
That doesn’t mean abandoning risk scores.
It means recognizing that wide areas of UNCERTAINTY exists, biology should trump probability.
Where PCCT Fits
Today’s guideline uses CAC as the gateway to imaging-guided prevention.
Tomorrow, I believe that gateway will become plaque-guided prevention.
Photon-Counting CT has the potential to move beyond calcium alone by providing a more complete assessment of plaque burden, composition, and biology.
Perhaps the next revolution in prevention won’t come from a better risk equation.
It will come from seeing atherosclerosis earlier, more completely, and more biologically.
Treat the plaque. Not just the predicted risk.”
Title: Imaging guided treatment of subclinical atherosclerosis—We’ve come a long way!
Authors: Eugenia Gianos, Ron Blankstein
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy
-
Sep 20, 2026, 01:04Omar Danoun: Levetiracetam May Increase Thromboembolic Risk With DOACs
-
Sep 20, 2026, 01:02Mohamed Abo-Aly: Which Antiseizure Medication is Safest for Patients on DOACs?
-
Sep 20, 2026, 00:58Hamza Rafiq: How Does a Deep Vein Thrombosis Become a PE?